The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Soft Tissue Sarcoma Market During 2026–2030?
The soft tissue sarcoma market has experienced substantial growth in recent years. It is projected to expand from $3.41 billion in 2025 to $3.7 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be attributed to factors such as improved cancer diagnostics, increased funding for oncology research, enhanced awareness of rare cancers, the accessibility of chemotherapy, and advancements in surgical procedures.
The soft tissue sarcoma market size is projected to experience robust expansion in the coming years, with expectations to reach $5.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. The anticipated growth during this period is driven by factors such as the approval of novel drugs, the expanding application of immunotherapy, an increase in molecular testing, the rising demand for personalized treatment, and advancements in oncology infrastructure. Prominent trends for the forecast period encompass the growing use of targeted therapies, enhanced genetic profiling, the expansion of combination treatment regimens, increased enrollment in clinical trials, and the broader adoption of multidisciplinary care approaches.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12211&type=smp
Which Economic Or Industry Drivers Are Impacting The Soft Tissue Sarcoma Market?
The increasing occurrence of cancer is projected to fuel the expansion of the soft tissue sarcoma market in the future. Cancer encompasses a wide range of diseases that can arise in any organ or tissue when abnormal cells multiply without control, extending beyond their normal limits and either spreading to other organs or infiltrating adjacent body parts. This escalation in cancer cases heightens the demand for diagnostic techniques, treatment protocols, and supportive care options to address the specific needs of individuals with various forms of cancer or sarcoma, thereby bolstering the soft tissue sarcoma market. For example, in July 2024, as reported by the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 daily cases, with males accounting for approximately 55% of these diagnoses. Consequently, the rising cancer incidence is propelling the growth of the soft tissue sarcoma market.
How Are The Various Segments Of The Soft Tissue Sarcoma Market Categorized?
The soft tissue sarcoma market covered in this report is segmented –
1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Immunotherapy Agents
2) By Chemotherapy: Doxorubicin, Ifosfamide, Gemcitabine, Other Chemotherapeutic Agents
3) By Anti-Angiogenesis Drugs: Bevacizumab, Pazopanib, Axitinib, Other Anti-Angiogenesis Agents
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy
5) By Other Treatments: Surgery, Clinical Trials, Supportive Care
What Trends Are Advancing Progress In The Soft Tissue Sarcoma Market?
Leading companies in the soft tissue sarcoma market are focusing on the development of innovative products to bolster their presence. For example, in November 2023, Mercy, a US-based non-profit Catholic healthcare organization, launched an inventive AI-driven texting initiative named The Chen Chemotherapy Model. This program is designed to proactively prevent chemotherapy-related hospitalizations. It employs a smart texting platform that sends daily messages to chemotherapy patients seven days a week, excluding weekends and holidays. The texts offer a list of symptoms, including diarrhea, pain, fever, fatigue, nausea or vomiting, or the option for no symptoms. Patients can select and rate their symptoms, and their responses may be escalated to their healthcare provider. The aim is to detect potential issues early and intervene before symptoms deteriorate, highlighting Mercy’s dedication to using technology for better patient care in chemotherapy.
Which Major Firms Influence Developments In The Soft Tissue Sarcoma Market?
Major companies operating in the soft tissue sarcoma market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.
Read the full soft tissue sarcoma market report here:
https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report
What Are The Top-Performing Regions Within The Soft Tissue Sarcoma Market?
North America was the largest region in the soft tissue sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Soft Tissue Sarcoma Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12211&type=smp
Browse Through More Reports Similar to the Global Soft Tissue Sarcoma Market 2026, By The Business Research Company
Sarcoma Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report
Central Nervous System Lymphoma Treatment Global Market Report
Soft Tissue Repair Global Market Report
https://www.thebusinessresearchcompany.com/report/soft-tissue-repair-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model